2. Protein Tyrosine Kinase/RTK PI3K/Akt/mTOR MAPK/ERK Pathway JAK/STAT Signaling Stem Cell/Wnt Apoptosis Autophagy
  3. Src PI3K JNK STAT EGFR Apoptosis Autophagy
  4. Peruvoside

Peruvoside  (Synonyms: Encordin)

Cat. No.: HY-108016 Purity: 99.32%
SDS COA Handling Instructions

Molarity Calculator

Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib.

For research use only. We do not sell to patients.

Peruvoside Chemical Structure

Peruvoside Chemical Structure

CAS No. : 1182-87-2

Size Price Stock Quantity
1 mg USD 260 In-stock
5 mg USD 780 In-stock
10 mg USD 1320 In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Peruvoside Related Antibodies

Top Publications Citing Use of Products

View All Src Isoform Specific Products:

View All Isoforms
Lck Fyn Blk

View All PI3K Isoform Specific Products:

View All Isoforms
PI3Kα PI3Kβ PI3Kγ PI3Kδ PI3KC2α PI3KC2β PI3KC2γ Vps34 PI3K PI3KC3 p120γ

View All JNK Isoform Specific Products:

View All Isoforms
JNK1 JNK2 JNK3 JNK

View All STAT Isoform Specific Products:

View All Isoforms
STAT3 STAT5 STAT6 STAT1

View All EGFR Isoform Specific Products:

View All Isoforms
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Peruvoside is a potent inhibitor of Src, PI3K, JNK, STAT, and EGFR. Peruvoside induces apoptosis and autophagy and possesses a broad spectrum of anticancer activity in breast, lung, liver cancers and leukemia. Peruvoside is a broad-spectrum and potent antiviral activity against positive-sense RNA viruses. Peruvoside sensitizes Gefitinib (HY-50895)-resistant tumour cells (A549, PC9/gef and H1975) to Gefitinib[1][2][3][4].

Cellular Effect
Cell Line Type Value Description References
L02 IC50
> 10 μM
Compound: 29
Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
Cytotoxicity against human LO2 cells after 48 hrs by MTT assay
[PMID: 26714048]
MGC-803 IC50
0.02 μM
Compound: 29
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay
[PMID: 26714048]
SW1990 IC50
0.02 μM
Compound: 29
Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay
Cytotoxicity against human SW1990 cells after 48 hrs by MTT assay
[PMID: 26714048]
In Vitro

Peruvoside (50-1000 nM, 24 h) inhibits the viability and proliferation in PC9, PC9/gef, H3255, and H1975 cell lines[1].
Peruvoside (0.005-0.5 μM, 72 h) sensitizes A549, PC9/gef and H1975 to Gefitinib when in combination with Gefitinib (0.01~0.5 μM)[1].
Peruvoside (0-100 μM, 24 h) induces cell cycle arrest and apoptosis in MCF-7, HpG2, and A549 cells[2.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Peruvoside Related Antibodies

Cell Proliferation Assay[1]

Cell Line: PC9, PC9/gef, H3255, and H1975 cell lines
Concentration: 0, 0.01, 0.05, 0.1, 0.5, 1 μM
Incubation Time: 24, 48, 72, 96 h.
Result: Inhibited the viabilities of TKI-sensitive and TKI-resistant cell lines at all tested time points.
Inhibited the EGFR-mutant lung cancer cell viability and proliferation with 24 h IC50s of 48 nM, 74 nM, 67 nM, 143 nM, 277 nM and 428 nM for A549, PC9, PC9/gef, H3255, H1975 and BEAS-2B cells, respectively.
Significantly inhibited the proliferation of A549 (48, 72, and 96 h) and H3255 (24, 48, 72, and 96 h) lungcancer cells.

Cell Viability Assay[1]

Cell Line: A549, PC9/gef and H1975 cell lines
Concentration: 0.005, 0.0075, 0.01, 0.025, 0.05, 0.5 μM (in combination with 0.01, 0.05, 0.1, 0.25, 0.5 μM Gefitinib)
Incubation Time: 72 h.
Result: Had synergistic effects on A549 cells at the combination of 0.005, 0.075, or 0.01 μM and a low dose of gefitinib (0.01 or 0.05 μM).
Increased the sensitivity of PC9/gef and H1975 cells to Gefitinib at 0.025 or 0.05 μM.

Apoptosis Analysis[2]

Cell Line: MCF-7, A549 and HepG2 cell lines
Concentration: 0-100 μM
Incubation Time: 24 h
Result: Induced cell cycle arrest and apoptosis with lethal concentrations of IC50 for (MCF-7 - 100 nM), (A549 – 100 nM) and (HepG2 - 100 nM), respec-tively.
Arrested cell cycle at G0/G1 in MCF-7, A549 and HepG2 cells.
Significantly decreased the transcription of Chk1, Chk2, CDK6 and Cyclin D1 cell cycle genes in MCF-7, A549, and HepG2 cells.
In Vivo

Peruvoside (0.1 mg/kg for i.p; once daily for 28 days) suppresses the tumour growth in lung cancer mice model[1].
Peruvoside (0.59 mg/kg for i.p; once daily for 7 days) reduces mortality in EV-A71-infected mice model[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Lung cancer mouse model[1]
Dosage: 0.1 mg/kg
Administration: Intraperitoneal injection (i.p.); Once daily for 28 days
Result: Reduced the tumour size to 129.9 mm3, which was significantly smaller than the control group (348 mm3).
Significantly decreased levels of phosphorylated Src Y419 in tumour tissues compared with control tissues.
Animal Model: EV-A71-infected mice model[4]
Dosage: 0.59 mg/kg
Administration: Intraperitoneal injection (i.p.); Once daily for 7 days
Result: Substantially reduced clinical scores based on physical symptoms of body weight, activity,breathing, movement, and dehydration.
Showed about 6 log reduction in viral titre with 99.9% efficacy in inhibiting virus.
Molecular Weight

548.66

Formula

C30H44O9
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C[C@@]([C@](C1)([H])CC2)(CC[C@@H]1O[C@H](O[C@H]3C)[C@H]([C@@H]([C@H]3O)OC)O)[C@](CC[C@@]45C)([H])[C@]2([H])[C@]4(CC[C@@H]5C(CO6)=CC6=O)O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : ≥ 250 mg/mL (455.66 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 1.8226 mL 9.1131 mL 18.2262 mL
5 mM 0.3645 mL 1.8226 mL 3.6452 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 1.8226 mL 9.1131 mL 18.2262 mL 45.5656 mL
5 mM 0.3645 mL 1.8226 mL 3.6452 mL 9.1131 mL
10 mM 0.1823 mL 0.9113 mL 1.8226 mL 4.5566 mL
15 mM 0.1215 mL 0.6075 mL 1.2151 mL 3.0377 mL
20 mM 0.0911 mL 0.4557 mL 0.9113 mL 2.2783 mL
25 mM 0.0729 mL 0.3645 mL 0.7290 mL 1.8226 mL
30 mM 0.0608 mL 0.3038 mL 0.6075 mL 1.5189 mL
40 mM 0.0456 mL 0.2278 mL 0.4557 mL 1.1391 mL
50 mM 0.0365 mL 0.1823 mL 0.3645 mL 0.9113 mL
60 mM 0.0304 mL 0.1519 mL 0.3038 mL 0.7594 mL
80 mM 0.0228 mL 0.1139 mL 0.2278 mL 0.5696 mL
100 mM 0.0182 mL 0.0911 mL 0.1823 mL 0.4557 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Peruvoside Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Peruvoside1182-87-2EncordinSrcPI3KJNKSTATEGFRApoptosisAutophagyPhosphoinositide 3-kinasec-Jun N-terminal kinaseEpidermal growth factor receptorErbB-1HER1non-small-cell lung carcinomalung cancerA549PC9/gefH1975GefitinibNSCLCleukemiaPositive-sense RNA virusesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Peruvoside
Cat. No.:
HY-108016
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.